Please check your internet connection and try again.
# Durveqtix (fidanacogene elaparvovec-dzkt)
## Overview
Durveqtix is an adeno-associated virus vector-based gene therapy. It delivers a functional copy of the human coagulation Factor IX (FIX) gene to hepatocytes, enabling the production of FIX to prevent or reduce the frequency of bleeding episodes in patients with Hemophilia B.
## Primary Indications
Treatment of adults with moderately severe to severe Hemophilia B (congenital Factor IX deficiency) who are currently using Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
## Adult Dosing
The recommended dose is **5 x 10¹¹ vector genomes (vg) per kilogram** of body weight, administered as a single intravenous infusion.
## Pediatric Dosing
Safety and efficacy have not been established in pediatric patients (under 18 years of age). Use in this population is currently not recommended.
## Dose Adjustments
No dose adjustments are permitted. The product is a one-time, single-dose infusion.
## Contraindications
There are no absolute contraindications listed in the FDA label beyond severe hypersensitivity to the active substance or any excipients.
## Adverse Effects
* **Common:** Infusion-related reactions, elevated liver enzymes (transaminitis), headache, nausea, and fatigue.
* **Serious:** Potential for hepatotoxicity triggered by immune responses to vector-bound capsid proteins; risk of thromboembolic events if factor levels overshoot target ranges.
## Key Drug Interactions
There are no formal drug-drug interaction studies. However, concomitant use of hepatotoxic drugs or drugs affecting coagulation (e.g., anticoagulants, antiplatelets) requires extreme caution due to the risk of fluctuating Factor IX levels and liver stress.
## Monitoring
* **Baseline:** Factor IX activity levels, inhibitor testing, and comprehensive liver function tests (LFTs).
* **Post-Infusion:** Monitor LFTs (ALT/AST) weekly for at least the first 3 months to detect immune-mediated hepatotoxicity.
* **Factor IX Activity:** Regularly monitor FIX levels to assess response and screen for potential thrombotic risk if levels exceed physiologic norms.
## Clinical Pearls
* **Immune Management:** Prophylactic corticosteroids are typically required starting before the infusion and continued as needed based on LFT monitoring to suppress capsid-specific immune responses.
* **One-Time Effect:** This therapy is intended as a one-time treatment; durability is an ongoing area of clinical study.
* **Inhibitors:** Patients with pre-existing antibodies to the AAV-Rh74 capsid are excluded from therapy.
* **Efficacy Lag:** Patients may require supplemental Factor IX prophylaxis for a period following infusion until endogenous production reaches therapeutic levels.
***
**Disclaimer:** This information is for educational purposes only. Clinical guidelines and prescribing information are subject to change. Always verify the current FDA-approved labeling and consult institutional protocols before administration.
